Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Investor Takeaway For investors seeking exposure to the GLP-1 boom in India, the key is to identify companies with proven capabilities in: Peptide synthesis Sterile injectable manufacturing Global regulatory compliance CDMO services with US/EU clients Recommended Monitoring: R&D updates and capacity expansions Any tie-ups with global GLP-1 players Clinical trial progress for biosimilar versions Regulatory approvals (USFDA, EMA) Export data to key markets (USA, Canada, China) Conclusion The weight loss drug boom is changing global healthcare and creating a huge business opportunity for Indian pharma companies
Most peptides act on cell-surface receptors
Song Y, Qu C, Srivastava KD, Yang N, Busse P, Zhao W, et al
Experimental GLP1 patches with microneedles have worked in animals, but animal skin is different from human skin, and these lab systems are not the same as the patches being sold to consumers
US$ 28.74
US$ 27.89
US$ 28.44
